Urologix Statistics
Total Valuation
Urologix has a market cap or net worth of 2,128.
| Market Cap | 2,128 |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Urologix has 21.28 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 21.28M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.26% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.56
| Current Ratio | 0.56 |
| Quick Ratio | 0.31 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -19.39 |
| Interest Coverage | -1.13 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -7.62% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 196,705 |
| Profits Per Employee | -76,525 |
| Employee Count | 61 |
| Asset Turnover | 1.67 |
| Inventory Turnover | 4.81 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | -50.09 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 53.23 |
| Average Volume (20 Days) | 5,872 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.13 |
Income Statement
In the last 12 months, Urologix had revenue of 12.00 million and -4.67 million in losses. Loss per share was -0.22.
| Revenue | 12.00M |
| Gross Profit | 5.66M |
| Operating Income | -874,000 |
| Pretax Income | -4.72M |
| Net Income | -4.67M |
| EBITDA | -373,000 |
| EBIT | -874,000 |
| Loss Per Share | -0.22 |
Balance Sheet
The company has 492,000 in cash and 5.33 million in debt, giving a net cash position of -4.84 million or -0.23 per share.
| Cash & Cash Equivalents | 492,000 |
| Total Debt | 5.33M |
| Net Cash | -4.84M |
| Net Cash Per Share | -0.23 |
| Equity (Book Value) | -8.06M |
| Book Value Per Share | -0.38 |
| Working Capital | -2.73M |
Cash Flow
In the last 12 months, operating cash flow was -263,000 and capital expenditures -12,000, giving a free cash flow of -275,000.
| Operating Cash Flow | -263,000 |
| Capital Expenditures | -12,000 |
| Free Cash Flow | -275,000 |
| FCF Per Share | -0.01 |
Margins
Gross margin is 47.13%, with operating and profit margins of -7.28% and -38.90%.
| Gross Margin | 47.13% |
| Operating Margin | -7.28% |
| Pretax Margin | -39.34% |
| Profit Margin | -38.90% |
| EBITDA Margin | -3.11% |
| EBIT Margin | -7.28% |
| FCF Margin | n/a |
Dividends & Yields
Urologix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.26% |
| Shareholder Yield | -2.26% |
| Earnings Yield | -219,360.90% |
| FCF Yield | -12,922.93% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Urologix has an Altman Z-Score of -34.33. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -34.33 |
| Piotroski F-Score | n/a |